Foghorn Therapeutics Inc. (FHTX) Tops Q2 EPS by 15c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• Oracle (ORCL) PT Raised to $250 at UBS Following Q1 Results